In murine MLL-AF9—one of the most common MFPs with poor outcomes—AML model studies, depletion of either DNMT1 [22], KDM1A/LSD1 [23], or DOT1L [24–26] severely impaired leukemic transformation and disrupted disease progression. This evidence concerns the gene KMT2A and acute myeloid leukemia.